These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 26992707)

  • 1. Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas.
    Chatterjee R; Edelman D
    J Gen Intern Med; 2016 Jun; 31(6):650. PubMed ID: 26992707
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
    Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
    J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
    Hamid Z; Simmons DL
    Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
    [No Abstract]   [Full Text] [Related]  

  • 5. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
    Orkaby AR; Cho K; Cormack J; Gagnon DR; Driver JA
    Neurology; 2017 Oct; 89(18):1877-1885. PubMed ID: 28954880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Impact of Hypoglycemic Agents on Severity and Extent of Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus Undergoing Myocardial Perfusion Scintigraphy.
    Biondi-Zoccai G; Pinto A; Versaci F; Procaccini E; Neri G; Sesti G; Uccioli L; Vetere M; Peruzzi M; Nudi F
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):162-70. PubMed ID: 27074768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sulphonylurea derivatives or insulin with metformin?].
    Tack CJ; van de Laar FA
    Ned Tijdschr Geneeskd; 2014; 158():A8239. PubMed ID: 25308229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of non-insulin-dependent diabetes mellitus with metformin.
    Guthrie R
    J Am Board Fam Pract; 1997; 10(3):213-21. PubMed ID: 9159660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
    Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
    Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.
    Gitt AK; Bramlage P; Schneider S; Tschöpe D
    Cardiovasc Diabetol; 2015 Feb; 14():13. PubMed ID: 25645672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
    Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
    Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.
    Tan MH; Glazer NB; Johns D; Widel M; Gilmore KJ
    Curr Med Res Opin; 2004 May; 20(5):723-8. PubMed ID: 15140339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
    Jil M; Rajnikant M; Richard D; Iskandar I
    Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
    Cvetković RS; Plosker GL
    Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin in the early management of diabetic complications.
    Miles JM
    J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?
    Groop L; Widén E
    Diabete Metab; 1991 May; 17(1 Pt 2):218-23. PubMed ID: 1936480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus.
    Brown JB; Nichols GA; Glauber HS; Bakst A
    Clin Ther; 1999 Jun; 21(6):1045-57. PubMed ID: 10440626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.